Publications by authors named "Jeremy D Gates"

Claim this Profile
P
Preoperative thyroid ultrasound is indicated in patients undergoing parathyroidectomy for primary hyperparathyroidism.
Cletus A Arciero, Zita S Shiue, Jeremy D Gates, George E Peoples, Alan P B Dackiw

J Cancer· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Elizabeth A Mittendorf, Guy T Clifton, Jarrod P Holmes, Kevin S Clive, Ritesh Patil, Jeremy D Gates

Cancer· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AE37: a novel T-cell-eliciting vaccine for breast cancer.
Alan K Sears, Sonia A Perez, Guy T Clifton, Linda C Benavides, Jeremy D Gates

Expert Opin Biol Ther· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Jarrod P Holmes, Guy T Clifton, Ritesh Patil, Linda C Benavides, Jeremy D Gates

Cancer· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
Linda C Benavides, Alan K Sears, Jeremy D Gates, Guy T Clifton, Kevin S Clive

Expert Rev Vaccines· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.
Jeremy D Gates, Guy T Clifton, Linda C Benavides, Alan K Sears, Mark G Carmichael

Vaccine· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
Ritesh Patil, Guy T Clifton, Jarrod P Holmes, Asna Amin, Mark G Carmichael, Jeremy D Gates

J Am Coll Surg· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.
Mark G Carmichael, Linda C Benavides, Jarrod P Holmes, Jeremy D Gates, Elizabeth A Mittendorf

Cancer· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preoperative thyroid ultrasound in all patients undergoing parathyroidectomy?
Jeremy D Gates, Linda C Benavides, Craig D Shriver, George E Peoples, Alexander Stojadinovic

J Surg Res· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Linda C Benavides, Jeremy D Gates, Mark G Carmichael, Ritesh Patil, Jarrod P Holmes

Clin Cancer Res· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
Jeremy D Gates, Mark G Carmichael, Linda C Benavides, Jarrod P Holmes, Matthew T Hueman

J Am Coll Surg· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Asna Amin, Linda C Benavides, Jarrod P Holmes, Jeremy D Gates, Mark G Carmichael

Cancer Immunol Immunother· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Jarrod P Holmes, Jeremy D Gates, Linda C Benavides, Matthew T Hueman, Mark G Carmichael

Cancer· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Jarrod P Holmes, Linda C Benavides, Jeremy D Gates, Mark G Carmichael, Matthew T Hueman

J Clin Oncol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis